Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 5, 2012, Pages 487-494

  Zhu, Ying ^a   Tang, Ren Kuan ^a   Zhao, Peng ^a   Zhu, Shi Sheng ^a   Li, Yong Guo ^a   Li, Jian Bo ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

5 aminosalicylic acid; meta analysis; ulcerative colitis

Indexed keywords

MESALAZINE;

DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MEDICATION ADHERENCE; MESALAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 84859328360     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328350fc81     Document Type: Review

References (24)

1. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12:6102-6108. (Pubitemid 44688157)
2. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43. (Pubitemid 36126514)
3. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96:2929-2933. (Pubitemid 32959535)
4. Kane SV, Hanauer SB. National adherence rates with IBD therapy: PO vs. PR (abstract). Am J Gastroenterol 2001; 96:S296.
5. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18:191-198. (Pubitemid 36951655)
6. Van Hees PA, Van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4:333-336. (Pubitemid 12098750)
7. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis 2006; 12:1107-1113. (Pubitemid 44847467)
8. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132:66-75. (Pubitemid 46108735)
9. Sandborn WJ, Balan G, Kuzmak B, Hanauer SB. Comparable pharmacokinetics (PK) of two delayed release formulations of oral mesalamine. Am J Gastroenterol 2007; 102:S465.
10. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily dosing versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1:170-173. (Pubitemid 37248066)
11. Kane S, Holderman W, Jacques P, Miodek T. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence 2008; 2:253-258.
12. Kruis W, Jonaitis L, Pokrotnieks J, Acute G, Mikhailova TL, Horynski M, et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 2008; 134 (Suppl 1):A489.
13. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol 2007; 47:334-342. (Pubitemid 46294708)
14. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5:95-102. (Pubitemid 46096842)
15. Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R. Randomized trial of once- or twice-daily MMXt mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57:893-902. (Pubitemid 351919522)
16. Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado ME, Eichler HG, Müller M. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003; 17:1163-1169. (Pubitemid 36605753)
17. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58:233-240.
18. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7:762-769.
19. Hussain FN, Ajjan RA, Kapur K, Moustafa M, Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15:53-62. (Pubitemid 32055586)
20. Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138:1286-1296, 1296.e1-3.
21. Prantera C, Kohn A, Campieri M, Caprilli R, Cottone M, Pallone F, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30:908-918.
22. Hawthorne AB, Stenson R, Gillespie D, Swarbrick ET, Dhar A, Kapur KC, et al. One-year investigator-blind randomized multicenter trial comparing asacol 2.4 g once daily with 800mg three times daily for maintenance of remission in ulcerative colitis. Inflamm Bowel Dis 2011. doi:10.1002/ ibd.21938. [Epub ahead of print].
23. Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33:313-322.
24. Jadad A. Randomised controlled trials-a user's guide. London: BMJ Books; 1998. pp. 97-100.